AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
CNBC
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from CNBC.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
CNBC (www.cnbc.com), a Tier B publisher, filed this report on . CurrentWire published this page 15 minutes later, on .
Signal breakdown
CurrentWire ranked this story 60.3 of 100 in the snapshot this page was rendered from.
- Freshness
- 34.3 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 4.5 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 34.3 of 35. How each signal is calculated.
Filed under Business · International · News.
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.